Lawyers and Settlements
What are you looking for?
Email to a friendEmail
Home Page >> Potential Lawsuit >> Anzemet IV Injection Withdrawn From Canadian Market

Anzemet IV Injection Withdrawn From Canadian Market Due to Potential Risk of Arrhythmias

Ottawa, ONT: Sanofi-aventis Canada Inc, in collaboration with Health Canada is informing patients of the withdrawal of ANZEMET® (dolasetron mesylate) intravenous injection as it is no longer to be used to prevent nausea and vomiting associated with chemotherapy. ANZEMET® helps prevent nausea and vomiting associated with chemotherapy.

New data show that the injectable form of ANZEMET® can potentially increase the risk of abnormal heart rhythm which may result in serious cardiac problems at the doses recommended for the prevention of nausea and vomiting. The injection form of ANZEMET® will be removed from the Canadian market as of May 10, 2011.

For further infomration about this issue, visit: http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2011/anzemet_pc-cp-eng.php

Legal Help

If you or a loved one has suffered illness or an adverse health event in this case, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.

Last updated on Apr-28-11
LEGAL HELP NOW!
Please complete this form to request a review of your complaint by an attorney.

First name:

Last name:

Email address:

Phone number(s):

State:

Zip Code:

Defendant:

Describe your complaint:

Subscribe to our free newsletter


There is absolutely no cost to you to submit this form. Doing so places you under no obligations and does not establish an attorney-client relationship.

Related Lawsuits

Legal Services:

Facebook





Better Business Bureau

CAALA

Best of the Web Approved

Public Justice
 
FAQ | TOS | Privacy | Disclaimer | About Us | Contact Us | Press | Advertise | Member Login | Site Map

This work is licensed under a Creative Commons Attribution-NoDerivs 3.0 Unported License © 2001-2012 Online Legal Media. All rights reserved.